Compare Peloton Interactive Inc (PTON) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Peloton Interactive Inc vs Twist Bioscience Corp — how do they compare? Peloton Interactive Inc trades at $4.92 (market cap $2.16B), while Twist Bioscience Corp trades at $154.45 (market cap $10.08B). The key difference: Twist Bioscience Corp is far larger — about 4.7× Peloton Interactive Inc's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Peloton Interactive Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Peloton Interactive Inc for 37 Days and Twist Bioscience Corp for 27 Days on average.
| PTON | TWST | |
|---|---|---|
Market Cap | $2.16B | $10.08B |
Volume | 11,369,487 | 4,229,037 |
Sector | Consumer Cyclical | Health |
52-Week High | $7.86 | $205.00 |
52-Week Low | $3.71 | $25.45 |
Typical Hold Time | 37 Days | 27 Days |
Enterprise Value | $2.66B | $10.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Peloton (PTON) trades at $4.85, down 0.41% on the day, as the stock remains under technical pressure with bearish moving average signals. Fundamentally, the company achieved its first full-year net profit in fiscal 2026 with a 2.58% margin, while revenue declined to $2.4B. Recent product launches include a new foldable Tread Flex treadmill and AI-powered coaching features, signaling continued turnaround efforts under CEO Peter Stern's leadership.
The outlook remains challenged despite profitability improvements, with analyst consensus pointing to significant upside (target $8.00) but technical weakness and declining subscriber counts creating headwinds. Key risks include execution of the turnaround strategy, competitive pressure in connected fitness, and high debt levels, though cost-cutting measures show early success.
TWST trades at $155.65, down 6.78% today, reflecting a bearish technical signal and recent earnings misses. Revenue growth is strong, rising to $376.57M in 2025, but profitability remains elusive with a net income margin of -31.66%. The company's partnership with Lilly TuneLab for AI-driven drug discovery has generated positive news flow, yet cash flow remains negative, and the stock trades at elevated valuation multiples like P/S of 22.01.
The outlook is mixed: strong analyst buy-side consensus (73% Buy) and strategic AI partnerships offer growth potential, but persistent losses, high cash burn, and bearish technicals pose significant risks. Investors face a trade-off between long-term innovation prospects and near-term financial instability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Peloton Interactive Inc
Peloton Interactive Inc operates an interactive fitness platform. It operates its business in two reportable segments: Connected Fitness Products and Subscription. Connected Fitness Product revenue consists of sales of bike and tread and related accessories, associated fees for delivery and installation, and extended warranty agreements. Subscription revenue consists of revenue generated from monthly Connected Fitness Subscription and Digital Subscription. The company generates the majority of the revenue from the sale of Connected Fitness Products.
Read more on PTON →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
